On November 5, 2019 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, reported it will host a cocktail reception featuring a panel discussion of Delmar’s glioblastoma multiforme (GBM) trial status with highly recognized thought leaders in GBM during the 2019 Society for NeuroOncology Annual Meeting in Phoenix, Ariz (Press release, DelMar Pharmaceuticals, NOV 5, 2019, View Source [SID1234550319]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will be held on November 22, 2019 at 4:15-5:30 PM MT at the JW Marriott Desert Ridge, 5350 E. Marriott Drive in Phoenix Ariz. in the Grand Sonoran Room (H-I). Panel participants to include:
John de Groot, M.D., professor and chairman ad interim, Department of Neuro-Oncology at The University of Texas M.D. Anderson Cancer Center
David Reardon, M.D., clinical director of the Center for Neuro-Oncology at the Dana Farber Cancer Institute and professor of Medicine at Harvard Medical School
Timothy Cloughesy, M.D., professor of neurology at the David Geffen School of Medicine at the University of California, Los Angeles and member of the UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center.
Nicholas Butowski, M.D., neuro-oncologist practicing at UCSF Medical Center in San Francisco, Calif. and director of translational research in neuro-oncology at the Brain Tumor Center
Zhong-ping Chen, M.D., founder chairman of the Department of Neurosurgery/Neuro-oncology at Sun Yat-sen University Cancer Center, China and lead investigator of the Company’s Phase 2 clinical trial of VAL-083 in first-line treatment of MGMT-unmethylated GBM
Naureen Quibria, Ph.D., Equity Research Associate, Maxim Group – Moderator
For information or to sign up to attend this event, please send an email request to [email protected].
A recording of the event’s proceedings will be available shortly following on the Company’s website, www.delmarpharma.com.